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Abstract
Tuberous Sclerosis Complex (TSC) is a highly variable autosomal dominant 
multisystem disorder characterized by the growth of benign tumors, epilepsy, and TSC-
associated neuropsychiatric disorders (TAND).  There is a high level of clinical variability, 
even within the same family.  While reproductive decisions always carry a level of 
uncertainty, individuals with highly variable genetic conditions like TSC must consider 
both the chance of passing on the condition and the uncertain clinical presentation.  There 
is currently no literature on factors influencing reproductive decisions of adults with TSC.  
To address this gap in understanding, we conducted an exploratory mixed-methods 
survey utilizing an anonymous online questionnaire to assess study participants’: 1) 
familiarity with the symptoms of TSC, 2) understanding of the risk of passing on TSC, 3) 
perceived disease burden/quality of life, and 4) family planning considerations.  A total of 
175 individuals aged 18-45 who were diagnosed with TSC were included in the final data 
set.  Participants were highly familiar with symptoms of TSC with an average symptom 
knowledge score of 86.64%.  Cortical tubers, angiofibromas, angiomyolipomas, and 
seizures were recognized as symptoms of TSC by more than 95% of participants.  
Lymphangioleiomyomatosis (LAM) was the least recognized symptom (75.29%), with 
females being statistically more likely to recognize the symptom than males.  Most 
participants (85.96%) were aware of the 50% recurrence risk of TSC.  Perceived disease 
burden was low with 58.58% viewing themselves as mildly or very mildly affected.  Our 
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disease burden/quality of life instrument found that a majority of participants reported 
that they felt different from those around them, that they were frustrated by their 
symptoms, that their symptoms made them anxious, and that they thought about their 
TSC at least some of the time.  Sleep disturbance and pain caused by TSC were also 
common.  However, a majority of participants felt like they were in control of their lives, 
felt good about their social life, felt comfortable meeting new people, and felt they had 
the support they needed.  Around 60% of our study population was considering having 
future children with the average desired number of children equaling 2.25.  Reproductive 
methods being considered included traditional conception (52.94%), adoption (45.10%), 
donor gametes or embryos (17.64%), and preimplantation genetic diagnosis ([PGD], 
50.00%).  Thematic analysis showed desire for biological children, personal health, desire 
to not pass on TSC, financial concerns, and fertility issues were major factors in choice of 
reproductive method.  Interest in prenatal testing was high with 67.44% stating they 
would test a hypothetical future pregnancy.  Thematic analysis showed being informed, 
considering termination of pregnancy, and accepting whatever happens as major themes 
for individuals’ interest or lack thereof in prenatal testing.   While more studies are 
needed, the results of this survey will help genetic counselors address reproductive 
concerns of clients with TSC.  In particular, this study points to education gaps in TSC 
clinical symptoms and the underlying genetics which should be addressed by genetic 
counselors and other health professionals who are counseling adults with TSC. 
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CHAPTER 1 
 
Literature Review
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Tuberous Sclerosis Complex 
Tuberous Sclerosis Complex (TSC) is a multisystem disorder characterized by the 
growth of hamartomas (benign tumors) in the skin, brain, heart, lungs, kidneys, and eyes 
(Islam & Roach, 2015).  Abnormalities in the brain can result in neurological and 
psychological manifestations including epilepsy, intellectual disability, and autism (Capal 
et al., 2017; Prather & de Vries, 2004).  Current estimates suggest that TSC affects 
between 1 in 6,000 to 1 in 10,000 births across all ethnicities (Northrup & Krueger, 2013).  
TSC is caused by an autosomal dominant mutation in one of two genes: TSC1 which 
encodes the protein hamartin, and TSC2 which encodes the protein tuberin (Nellist et al., 
1993; vanSlegtenhorst et al., 1997).  Hamartin and tuberin bind to form a protein complex 
which regulates cell growth, size, and proliferation through the mammalian target of 
rapamycin (mTOR) pathway (Caban, Khan, Hasbani, & Crino, 2017).  Mutations in either 
gene can result in the protein complex failing to inhibit mTOR activity resulting in 
hyperactivation and uncontrolled cell growth and proliferation (Caban et al., 2017).  
Current genetic testing methods can identify a pathogenic variant in 75 to 90% of 
individuals, with two-thirds possessing a TSC2 pathogenic variant while the remaining 
third possess a TSC1 pathogenic variant (Peron, Au, & Northrup, 2018).  While some 
symptoms (i.e., intellectual disability, autism spectrum disorder, etc.) are seen more 
frequently in individuals with TSC2 pathogenic variants, there is little genotype-
phenotype correlation and individuals within the same family can vary from mildly to 
severely affected (Caban et al., 2017; Dabora et al., 2001; Peron et al., 2018).  The 
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phenotype depends on the age of the patient, the number and size of lesions, the organs 
involved, and the exact location of the lesions (Whittemore, Sampson, & Gomez, 1999).   
Physical Manifestations 
While lesions can occur anywhere in the body, the skin and the brain are the most 
commonly affected organs with lesions occurring in more than 90% of individuals 
(Wataya-Kaneda et al., 2017).  Possible skin lesions include hypomelanotic macules or 
“ash leaf spots,” confetti lesions, facial angiofibromas, shagreen patches, fibrous cephalic 
plaques, and periungual fibromas (Northrup & Krueger, 2013).  Brain structure 
abnormalities include cortical tubers, white matter radial migration lines, subependymal 
nodules (SEN), and subependymal giant cell astrocytomas (SEGA) (Northrup & Krueger, 
2013).  Benign tumors may also grow in the heart (i.e., rhabdomyomas), kidney (i.e., 
angiomyolipomas), and eyes (i.e., retinal hamartomas) (Northrup & Krueger, 2013). 
While the tumors associated with TSC are typically benign, they nonetheless have 
significant impact on morbidity and mortality (Amin, Lux, Calder, et al., 2017).  One major 
health concern is kidney damage and possible renal failure resulting from 
angiomyolipomas, cysts, or in rare cases renal cell carcinomas, particularly in individuals 
over the age of 30 (Rentz et al., 2018).  Some individuals with TSC may also have features 
of polycystic kidney disease due the proximity of the PKD1 gene to the TSC2 gene on 
chromosome 16 (Caban et al., 2017).  Individuals with large mutations in this region 
typically have earlier onset and more severe kidney disease than seen in typical TSC cases.  
Around 30% of women with TSC develop lymphangioleiomyomatosis (LAM), a lung 
disorder characterized by overgrowth of smooth muscle and replacement of the 
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parenchyma with cysts resulting in progressive loss of respiratory function, possible 
pneumothorax, and eventual respiratory failure (Frost & Hulbert, 2015).  It is believed 
that LAM predominantly affects females because LAM lesions express estrogen and 
progesterone receptors (Berger, Khaghani, Pomerance, Yacoub, & Coombes, 1990). 
Neurological Manifestations 
In addition to the growth of benign tumors, individuals with neurological 
involvement may experience epilepsy and TSC-associated neuropsychiatric disorders 
(TAND) including developmental delay, intellectual disability, autism spectrum disorder, 
and behavioral disturbances (Curatolo, Moavero, & de Vries, 2015).  Seizures affect 
approximately 72 to 85% of individuals with TSC and persist regardless of treatment in 
roughly 60% of cases (Chu-Shore, Major, Camposano, Muzykewicz, & Thiele, 2010; 
Curatolo et al., 2015).  Early-onset or uncontrolled seizures, particularly infantile spasms, 
are associated with developmental delay, intellectual deficits, and behavioral disorders 
(Capal et al., 2017; F. E. Jansen et al., 2008; Kopp, Muzykewicz, Staley, Thiele, & Pulsifer, 
2008; Numis et al., 2011; Winterkorn, Pulsifer, & Thiele, 2007).  Approximately half of 
children with TSC have intellectual disability ranging from borderline to profound (de 
Vries et al., 2018; Winterkorn et al., 2007).  In children with normal intellectual ability, 
between 30% and 60% will experience learning difficulty in reading, writing, spelling, and 
mathematics (Curatolo et al., 2015; de Vries et al., 2018).  Behavioral disturbances are 
common with around 40 to 50% of children diagnosed with autism spectrum disorder, 
and around 50% diagnosed with attention deficit hyperactivity disorder (Curatolo et al., 
2015).  Individuals can also exhibit aggressive outbursts, impulsivity, overactivity, temper 
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tantrums, sleep difficulties, mood swings, anxiety, and self-injury (Prather & de Vries, 
2004).  The Tuberous Sclerosis Registry to Increase Disease Awareness (TOSCA) natural 
history study found that the most common behavioral problems were overactivity (45%), 
sleep difficulties (43.9%), impulsivity (42.7%), anxiety (33.3%), mood swings (29.8%) and 
depressed mood (19.2%) (de Vries et al., 2018).  The rates and types of TAND also vary by 
age with a larger proportion of adults experiencing anxiety (50.9%), depressed mood 
(43.9%), and mood swings (40.8%) (de Vries et al., 2018).  TAND are some of the most 
difficult symptoms for families to manage and parents often report significant stress due 
to their child’s intellectual deficits and behavioral problems (Kopp et al., 2008). 
Variable Expression 
As an autosomal dominant condition with nearly full penetrance, individuals with 
TSC have a 50% chance of passing on their condition to each of their children.  While the 
genotypic risk is clear, the phenotypic risk is less certain.  In some individuals, the 
condition is so mild that it is only diagnosed when a more severely affected family 
member is born (Caylor et al., 2018; Fox et al., 2017; Robyr, Bernard, Roume, & Ville, 
2006).  This high level of phenotypic variability poses a challenge when affected 
individuals are faced with family planning decisions since it is impossible to predict the 
degree to which a child may be affected.  TSC also has a relatively high de novo mutation 
rate with around two out of three cases occurring in individuals with no family history 
(Caban et al., 2017).  Due to the rarity of the condition, individuals with de novo mutations 
may have no exposure to the phenotypic range of TSC outside their own experience.  
While reproductive decisions always carry a level of uncertainty, individuals with highly 
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variable genetic conditions like TSC must first contend with the chance of passing on the 
condition, and then with the uncertain clinical expression.  Studies on reproductive 
decision making have shown that the actual calculated genetic risk interacts with the 
perceived burden of the condition to determine an individual’s reproductive choices 
(Hallowell & Richards, 1997).  Thus, perceived quality of life would likely be a major factor 
in the reproductive decisions of individuals with TSC. 
Quality of Life with TSC 
Jansen et al. (2017) recently presented the results of a survey assessing quality of 
life in 111 patients including 45 adults with TSC.  They found that 55.6% of adults with TSC 
reported that their career, education, and interpersonal relationships outside the family 
had been adversely affected by TSC.  Nearly half (48.6%) reported anxiety or depression, 
and 40% reported significant pain or discomfort.  These preliminary findings suggest that 
TSC has a substantial impact on individuals’ health and wellbeing.  While there are 
currently no studies assessing the impact of quality of life on reproductive decisions in 
TSC patients, the findings of Jansen et al. suggest that a higher perceived disease burden 
may negatively impact reproductive decisions. 
Reproductive Decisions in Variable Genetic Conditions 
While reproductive decisions of individuals with TSC have yet to have been 
studied, research into other dominant conditions with variable expressivity can provide 
insights into how individuals with TSC may approach reproductive decisions.  For example, 
one study found that 62% of individuals diagnosed with Marfan syndrome (a connective 
tissue disorder affecting the bones, skin, eyes, and cardiovascular system) felt the 
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condition significantly influenced reproductive decision-making (Peters, Kong, Hanslo, & 
Biesecker, 2002).  This was particularly true for individuals with a family history or those 
who were diagnosed before the age of fifteen.  The influence of Marfan syndrome on 
reproductive decision-making correlated with the perception that Marfan syndrome had 
significant negative consequences on the affected individual’s life (Peters et al., 2002).  
Additionally, individuals with a family history and therefore presumably more exposure 
to possible negative consequences of the condition were less likely to have children than 
those without a family history (Peters et al., 2002).   
A study on individuals affected by Neurofibromatosis 1 (NF1) had similar findings 
with participants stating that the variability of the condition was a major complicating 
factor in family planning (Benjamin et al., 1993).  Like TSC, NF1 is characterized by patches 
of skin pigment variation and the growth of benign skin tumors which can range from mild 
cosmetic differences to severe disfigurement.  Affected individuals may also experience 
learning difficulties (30% of cases) and epilepsy (4% of cases).  Benjamin et al. (1993) 
found that a majority of their study respondents perceived themselves as more severely 
affected than medical classification would suggest, particularly those who were 
concerned about the cosmetic aspects of the condition.  NF1 posed a significant burden 
for many respondents with 63% reporting difficulty in school, 48% reporting anxiety 
during adolescence due to cosmetic symptoms, and 17% reporting teasing.  In a similar 
study, severely affected individuals reported that they did not see themselves as likely to 
get married due to their condition, indicating that NF1 had a negative influence on their 
quality of life (Ponder et al., 1998).  When asked about hypothetical children, half of 
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severely affected individuals reported that they would not want to have children with NF1 
(Ponder et al., 1998).  The study also found that affected parents who had more severely 
affected children reported feelings of distress and guilt for having known the risk of 
passing on NF1 without fully understanding the chance of increased severity in their child 
(Ponder et al., 1998). 
Stigmatization 
 As seen in the studies on NF1, one major aspect of quality of life for individuals 
with visible differences is actual or perceived stigmatization.  This is particularly true for 
individuals with facial differences.  A recent study on individuals with facial port wine stain 
found a moderate negative influence on quality of life, particularly emotional wellbeing 
(Hagen, Grey, Korta, & Kelly, 2017).  Participants reported depression (26.2%) and anxiety 
(33.6%) due to their facial differences, with women having more emotional effects.  Other 
studies on children and teenagers with port wine stain showed increased rates of bullying, 
teasing, and social isolation (Vivar & Kruse, 2018).  For individuals with TSC, growth of 
angiofibromas may lead to facial disfigurement which can negatively impact quality of life 
(Crall et al., 2016).  While treatment with topical sirolimus ointment can greatly improve 
the appearance of angiofibromas and have a positive impact on quality of life (Amin, Lux, 
Khan, & O'Callaghan, 2017), this treatment has only been available since 2010 (Haemel, 
O'Brian, & Teng, 2010).  Therefore, many adults with TSC likely grew up with 
stigmatization for their facial difference that may have had a negative impact on their 
self-esteem and quality of life.  When thinking about their future children, adults with TSC 
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will likely remember these past experiences and possibly imagine a similar situation for 
their children. 
Prenatal Testing and Selective Reproduction 
While perceived quality of life appears to greatly affect reproductive decisions of 
individuals with dominant genetic conditions, interest in prenatal testing varies.  For NF1, 
greater exposure to the condition appears to lessen the likelihood of expressing interest 
in prenatal testing.  A recent study of pregnant women with NF1 referred to an obstetrics 
center in Italy found that 90% of women with a family history of NF1 were not interested 
in prenatal testing while 83% of those with no family history were interested in prenatal 
testing (Cesaretti et al., 2013).  Benjamin et al. (1993) found that 12 out of 29 respondents 
considering future children would be interested in prenatal diagnosis of NF1, and of those, 
three would consider termination of the pregnancy if affected.  While Benjamin et al. did 
not report whether respondents interested in prenatal testing had a family history of NF1, 
the authors noted that those who stated they would consider termination rated their own 
symptoms or their family member’s symptoms of NF1 as moderate.  This result suggests 
that individuals considering termination may have less exposure to individuals with 
severe symptoms who are nonetheless living a quality life.  In the case of Marfan 
Syndrome, a majority (69%) of study participants expressed interest in prenatal diagnosis, 
though the study did not address whether the interest was for increased knowledge 
during pregnancy or with the intention to selectively terminate (Peters et al., 2002).  The 
study also did not address whether those expressing interest in prenatal testing had a 
family history of Marfan Syndrome or the severity of their symptoms.   
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While interest in prenatal diagnosis does not necessarily equate to interest in 
termination of affected pregnancies, people often conflate the two concepts.  Therefore, 
when asking study participants about their reproductive decisions and interest in prenatal 
testing it is important to recognize that participants may interpret the question as interest 
in selecting against an affected child either by using alternative reproductive methods or 
terminating affected pregnancies.  A recent study of adults with physically or cognitively 
impairing genetic conditions found that support or opposition to selective reproduction 
depended upon the participant’s perceived quality of life and the quality of life they 
assigned to others with the same condition (Boardman & Hale, 2018).  Individuals who 
supported selective reproduction often described experiences of social stigma, the 
impairments and intensive treatments associated with their condition, and limitations to 
relationships, employment, and housing as barriers to a full and successful life (Boardman 
& Hale, 2018).  However, negative views of a condition did not necessarily mean 
individuals would support selective reproduction.  Individuals who incorporated their 
condition into their identity tended to be ambivalent or opposed to selective 
reproduction as a societal problem of inaccurately using a single aspect of an individual 
to determine the value of the whole (Boardman & Hale, 2018).
11 
CHAPTER 2 
 
Reproductive-Aged Adults Diagnosed with Tuberous Sclerosis Complex (TSC): 
Understanding of Clinical Variability, Perceived Disease Burden, and  
Reproductive Decision-Making
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Introduction 
 Preconception and prenatal counseling are important aspects of genetic 
counseling.  As modern advances in genetics and reproductive technologies make it 
possible to not only diagnose genetic conditions before a child is born, but also to select 
embryos based on the presence or absence of a condition, it becomes even more 
important for genetic counselors to understand the thoughts and needs of clients making 
these reproductive decisions.  While reproductive decisions always carry a level of 
uncertainty, individuals with highly variable genetic conditions must first contend with 
the chance of passing on the condition, and then with the uncertain genotype-phenotype 
relationship.  Studies on reproductive decision-making have shown that the actual 
calculated genetic risk interacts with the perceived burden of the condition to determine 
an individual’s reproductive choices (Hallowell & Richards, 1997).  As a result, 
reproductive decisions would likely be highly influenced by an individual’s knowledge of 
the clinical spectrum of a condition as well as their own experience. 
Tuberous Sclerosis Complex 
Tuberous Sclerosis Complex (TSC) is a highly variable multisystem disorder 
characterized by the growth of hamartomas (benign tumors) in the skin, brain, heart, 
lungs, kidneys, and eyes (Islam & Roach, 2015).  Current estimates suggest that TSC affects 
between 1 in 6,000 to 1 in 10,000 births across all ethnicities (Northrup & Krueger, 2013).  
TSC is caused by an autosomal dominant mutation in one of two genes: TSC1 which 
encodes the protein hamartin, and TSC2 which encodes the protein tuberin (Nellist et al., 
1993; vanSlegtenhorst et al., 1997).  Hamartin and tuberin form a protein complex which 
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regulates cell growth, size, and proliferation through the mammalian target of rapamycin 
(mTOR) pathway (Caban et al., 2017).  Mutations in either gene can result in the protein 
complex failing to inhibit mTOR activity resulting in hyperactivation and uncontrolled cell 
growth and proliferation (Caban et al., 2017).   
While TSC is considered fully penetrant, the phenotype depends on the age of the 
individual, the number and size of lesions, the organs involved, and the exact location of 
the lesions (Whittemore et al., 1999).  The skin and brain are the most commonly affected 
organs with lesions occurring in more than 90% of individuals (Wataya-Kaneda et al., 
2017).  Skin abnormalities range from mild skin differences such as hypomelanotic 
macules to disfiguring facial angiofibromas and fibrous plaques (Northrup & Krueger, 
2013).  Brain structure abnormalities include cortical tubers, white matter radial 
migration lines, subependymal nodules (SEN), and subependymal giant cell astrocytomas 
(SEGA) (Northrup & Krueger, 2013).  Individuals with TSC may also have benign tumors in 
the heart (i.e., rhabdomyomas), kidney (i.e., angiomyolipomas [AMLs]), and eyes (i.e., 
retinal hamartomas) (Northrup & Krueger, 2013).   
While the tumors associated with TSC are typically benign, they nonetheless have 
significant impact on morbidity and mortality (Amin, Lux, Calder, et al., 2017).  One major 
health concern is kidney damage and possible renal failure resulting from 
angiomyolipomas, cysts, or in rare cases renal cell carcinomas, particularly in individuals 
over the age of 30 (Rentz et al., 2018).  Around 30% of female TSC patients develop 
lymphangioleiomyomatosis (LAM), a lung disorder characterized by overgrowth of 
smooth muscle and replacement of the parenchyma with cysts resulting in progressive 
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loss of respiratory function, possible pneumothorax, and eventual respiratory failure 
(Frost & Hulbert, 2015; Moir, 2016).  Seizures affect approximately 72 to 85% of 
individuals and persist regardless of treatment in roughly 60% of cases (Chu-Shore et al., 
2010; Curatolo et al., 2015).   
In addition to the physical manifestations of the condition, TSC-associated 
neuropsychiatric disorders (TAND) including developmental delay, intellectual disability, 
autism spectrum disorder, and behavioral disturbances can have a major impact on 
individuals and families (Curatolo et al., 2015).  Approximately half of children diagnosed 
with TSC have autism spectrum disorder and/or intellectual disability ranging from 
borderline to profound (de Vries et al., 2018; Winterkorn et al., 2007).  Among children 
with typical intellectual ability, 30 to 60% will experience learning difficulty (Curatolo et 
al., 2015; de Vries et al., 2018).  Behavioral disturbances are common and include 
overactivity (45%), sleep difficulties (43.9%), impulsivity (42.7%), anxiety (33.3%), mood 
swings (29.8%) and depressed mood (19.2%) (de Vries et al., 2018).  The rates and types 
of TAND also vary by age with a larger proportion of adults experiencing anxiety (50.9%), 
depressed mood (43.9%), and mood swings (40.8%) (de Vries et al., 2018).  TAND are 
some of the most difficult symptoms for families to manage and parents often report 
significant stress due to their child’s intellectual deficits and behavioral problems (Kopp 
et al., 2008). 
While these physical and psychological symptoms would clearly impact an 
individual’s daily life, perceptions of quality of life have only recently been assessed.  
Jansen et al. (2017) presented the results of a survey assessing quality of life in 111 
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patients including 45 adults with TSC.  They found that 55.6% of adults with TSC reported 
that their career, education, and interpersonal relationships outside the family had been 
adversely affected by TSC.  Nearly half (48.6%) reported anxiety or depression, and 40% 
reported significant pain or discomfort.  These preliminary findings suggest that TSC has 
a substantial impact on individuals’ health and wellbeing.  While there are currently no 
studies assessing the impact of quality of life on reproductive decisions in TSC patients, 
the findings of Jansen et al. suggest that perceived disease burden may be an important 
factor in family planning. 
Reproductive Decision Making 
As an autosomal dominant condition with nearly full penetrance, individuals with 
TSC have a 50% chance of passing on their condition to each of their children.  However, 
while the genotypic risk is clear, the phenotypic risk is less certain.  In some individuals, 
the condition is so mild that it is only diagnosed when a more severely affected family 
member is born (Caylor et al., 2018; Fox et al., 2017; Robyr et al., 2006).  This high level 
of phenotypic variability poses a challenge when adults with TSC are faced with family 
planning decisions.  Due to the rarity of the condition and high de novo mutation rate of 
roughly 70%, adults with TSC may have no exposure to the phenotypic range of the 
condition outside their own subjective experience.  Individuals who perceive their 
condition as having a significant negative impact on their lives may view the possibility of 
passing on TSC to a child more negatively than individuals who have had a more neutral 
or positive experience.   
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While reproductive decisions of individuals with TSC have yet to have been 
studied, research into other dominant conditions with variable expressivity can provide 
insights into how individuals with TSC may approach reproductive decisions.  One study 
found that 62% of individuals diagnosed with Marfan syndrome (a connective tissue 
disorder affecting the bones, skin, eyes, and cardiovascular system) felt the condition 
significantly influenced reproductive decision-making (Peters et al., 2002).  This was 
particularly true for individuals with a family history or those who were diagnosed before 
the age of fifteen.  The influence of Marfan syndrome on reproductive decision-making 
correlated with the perception that Marfan syndrome had significant negative 
consequences on the affected individual’s life (Peters et al., 2002).   Additionally, 
individuals with a family history and therefore presumably more exposure to possible 
negative consequences of the condition were less likely to have children than those 
without a family history (Peters et al., 2002).   
A study on individuals affected by Neurofibromatosis 1 (NF1) had similar findings 
with participants stating that the variability of the condition was a major complicating 
factor in family planning (Benjamin et al., 1993).  Like TSC, NF1 is characterized by patches 
of pigment variation and the growth of benign skin tumors which can range from mild 
cosmetic differences to severe disfigurement.  Affected individuals may also experience 
learning difficulties (30% of cases) and epilepsy (4% of cases).  Benjamin et al. (1993) 
found that a majority of their study respondents perceived themselves as more severely 
affected than medical classification would suggest, particularly those who were 
concerned about the cosmetic aspects of the condition.  NF1 posed a significant burden 
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for many respondents with 63% reporting difficulty in school, 48% reporting anxiety 
during adolescence due to cosmetic symptoms, and 17% reporting teasing.  In a similar 
study, severely affected individuals reported that they did not see themselves as likely to 
get married due to their condition, indicating that NF1 had a negative influence on their 
quality of life (Ponder et al., 1998).  When asked about hypothetical children, half of 
severely affected individuals reported that they would not want to have children with NF1 
(Ponder et al., 1998).  The study also found that affected parents who had more severely 
affected children reported feelings of distress and guilt for having known the risk of 
passing on NF1 without fully understanding the chance of increased severity in their child 
(Ponder et al., 1998). 
Study Aims 
To better counsel adult clients with TSC, genetic counselors need to understand 
what factors weigh most heavily in their family planning decisions.  Adults with TSC would 
have to consider their knowledge of TSC, their personal experience with the condition, 
and their desired family structure when making family planning decisions.  It is not 
currently clear whether individuals with a family history of TSC perceive the chance of 
passing on TSC to a child differently from individuals who have a de novo mutation.  
Additionally, it is unclear whether adults with TSC are familiar with reproductive options 
such as preimplantation genetic diagnosis (PGD) or prenatal genetic diagnosis.  To utilize 
these options, an individual with TSC would need to know their genetic mutation.  It is 
not currently known what percent of adults with TSC know their genetic mutation status.  
This study addresses these gaps in understanding through an exploratory mixed-methods 
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survey utilizing an anonymous online questionnaire to assess study participants’: 1) 
familiarity with the symptoms of TSC, 2) understanding of the risk of passing on TSC to a 
child, 3) perceived disease burden/quality of life, and 4) family planning considerations. 
 
Methods 
Participants 
The overarching goal of this research is to better understand how adults 
diagnosed with TSC make reproductive decisions.  Therefore, participation was limited to 
individuals who have been diagnosed with TSC who are between the ages of 18 to 45 
years.  While we recognize that an age cut-off of 45 may not encompass all adults with 
TSC who may be making family planning decisions, we wanted to limit the age range to 
those who were most likely to be making current or future decisions.   
Recruitment for the survey was conducted with the aid of the TS Alliance, a non-
profit dedicated to advocating for TSC, supporting research, and providing information 
and support for affected individuals and families.  The survey was advertised through 
flyers (Appendix A) distributed at the TS Alliance table at the 2018 World TSC Conference 
in Dallas, TX on July 26 - 29, 2018.  Digital copies of the flyer were also distributed through 
the TS Alliance Facebook groups, online community support pages, and through the 
monthly “Adults with TSC” email newsletter.  Recruitment advertisements were posted 
from July to November 2018.  To increase survey participation, a $25 Amazon e-gift card 
drawing was offered as incentive.  Participants who chose to enter the drawing provided 
either an email or phone number where the e-gift card could be delivered.  At the end of 
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the survey period, all entries were run through an online random selection tool and the 
e-gift card was sent to the winning phone number or email.  Direct financial or academic 
compensation for completing the survey was not offered to avoid coercion.   
Participation in the survey and drawing was completely voluntary.  Consent was 
obtained through the questionnaire welcome page (Appendix B) which outlined the goals 
and format of the survey.  Participants were informed that they could stop at any time or 
skip any question except for the participation eligibility questions.  The welcome page 
stated that by clicking “next” to proceed to the questionnaire, the participant was 
providing informed consent.  To establish participation eligibility, the questionnaire 
begins with two screener questions.  Individuals who did not meet participation eligibility 
were automatically redirected to a thank-you page and did not proceed with the 
questionnaire. 
A total of 224 individuals attempted to participate in the online survey.  The first 
eligibility question screened out seven individuals who did not have a diagnosis of TSC, 
leaving 217 individuals to move on to the next screener question.  The second eligibility 
question screened out another seven individuals who were not aged between 18 and 45, 
leaving 210 to complete the questionnaire.  Four people did not complete any of the 
questions after the first two questions and were manually deleted from the data set.  Of 
the 206 individuals who answered Question 3, two individuals answered that their current 
age was over 45 thereby disqualifying themselves from participating in the survey.  These 
individuals’ responses were manually deleted from the data set leaving 204 participants 
eligible for the study.  Twenty-nine participants did not provide any symptoms of TSC they 
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experience.  Due to the important role participants’ symptoms play in our research 
questions, we manually removed these 29 responses from the data set leaving 175 
participants in the final analysis.  Participant demographics are summarized in Table 2.1. 
Instrumentation 
 In order to assess study aims, we conducted an anonymous online mixed-methods 
survey.  The purpose-designed questionnaire was hosted on a password-protected 
SurveyMonkey.com account.  The questionnaire included twenty-four questions which 
covered demographics, knowledge of TSC, symptoms of the individual and affected family 
members, reproductive decisions and quality of life (Appendix B).  Personally identifiable 
information was not collected in this survey.  The SurveyMonkey software has skip logic 
which allowed us to use the participants’ responses to certain questions to determine if 
they should proceed to the next question or be redirected to a later part of the 
questionnaire if the next question did not pertain to them.  Therefore, while the 
questionnaire included 24 total questions, not every participant was asked each question.  
Our questionnaire included a purpose-designed disease burden/quality of life instrument.  
The questions included in the disease burden/quality of life instrument were based on 
factors that were included in the quality of life survey by Jansen et al. (2017). 
Procedures  
To assess knowledge of TSC, participants were asked if a listed symptom was or 
was not a symptom of TSC.  Correct answers were given a score of “1” while incorrect or 
blank answers were given a score of “0” for a total of 24 possible points.  To assess 
familiarity with symptoms of TSC, participants were asked if they or an affected family 
21 
member experienced the specified symptom.  Symptom severity scores were calculated 
for participants and family members by adding the total number of TSC symptoms 
experienced to create an overall score.  Participants were also given a score for facial 
symptom severity (i.e., presence of angiofibromas and forehead plaques).  Some 
participants who did not previously state that they had a family member with TSC 
nonetheless selected certain TSC associated symptoms were present in family members.  
Since some symptoms (i.e., seizures) could be present in family members who did not 
have TSC, we filtered responses so that only the responses from individuals who stated 
they had an affected family member were counted and scored.  Open-ended questions 
eliciting a numerical response (i.e., Questions 3, 7, 8, 11, and 13) were standardized by 
converting text to a number (e.g., “one” was converted to “1”), rounding to whole 
numbers (e.g., “7½” was converted to 8), and selecting the higher number of a range (e.g., 
“4 to 6” was converted to 6).  Disease burden was assessed by asking participants to rate 
how often they agreed with a statement on a scale of “never” to “very often.”  Responses 
were converted to a five-point Likert score.  Negative statements were scored one for 
“never” to five for “very often.”  Positive statements were scored in reverse with a score 
of five for “never” and one for “very often.”  Responses were added together to create a 
disease burden score with lower values representing less burden and higher values 
representing more burden.  While most questions were quantitative in nature, questions 
regarding reproductive decisions combined quantitative measurements with qualitative, 
open-ended responses.  We chose to use mixed-methods to better identify themes that 
influenced participants’ reproductive decisions.  Mixed-methods research combines 
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quantitative and qualitative methodology to investigate questions that cannot be 
sufficiently answered by a single method alone (Castro, Kellison, Boyd, & Kopak, 2010).  
Data Analysis 
Data was analyzed using SPSS Statistics software (Armonk, NY: IBM Corporation).  
Descriptive statistics were used to describe data, inferential statistics were used to look 
at group differences, and grounded theory was used to analyze open-ended questions.  
Open-ended responses were read by the principal investigator and thematically analyzed 
and scored. 
 
Results 
Participant Demographics 
Our survey population of 175 individuals was normally distributed between 18 to 
45 years of age with a mean of 31.85 years (SD = 7.65) and a median of 32 years.  Sex was 
skewed toward females (n = 137, 78.29%); only one-fifth of the population was male (n = 
35, 20.00%) and a small minority (n = 3, 1.71%) preferred not to answer their sex.  A 
majority of participants (62.79%) were either married (n = 70, 40.70%) or in a serious 
relationship or engaged (n = 38, 22.09%).  Participants were highly educated with 42.44% 
having a bachelor’s degree or higher.  See Table 2.1 for more detailed participant 
demographics.  Fifty-three participants (30.29%) currently have children.  The average 
number of children was 1.79 with a median of two children.  Fifty-eight participants 
(33.14%) reported at least one affected family member.  Eleven (18.96%) of the 
participants were from multigenerational families with both a parent and at least one 
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child diagnosed with TSC.  Participants’ current family structure is summarized in Table 
2.2.   
Diagnosis of TSC 
When asked at what age they were diagnosed with TSC, seven (4.00%) reported 
they were diagnosed prenatally, 43 (24.57%) reported they were diagnosed under the 
age of one, and 125 (71.43%) reported they were diagnosed over the age of one.  Of those 
who were diagnosed over the age of one, answers ranged from one to 40 years of age 
with an average age of 14.66 (SD = 10.69) and a median age of 12.  The median age at 
diagnosis for the whole survey population was seven.  The average age at diagnosis was 
not calculated for the whole survey population due to the difficulty of calculating ages for 
prenatal diagnoses, and the fact we did not specifically ask the age in months for 
individuals diagnosed under the age of one.  Figure 2.1 shows the range of ages at 
diagnosis.   
When asked if they have had genetic testing for TSC, 102 (58.62%) responded yes, 
55 (31.61%) responded no, and 17 (9.77%) were uncertain.  Genetic testing results are 
summarized in Figure 2.2.  A pathogenic variant was found for 63.73% of those who had 
testing, with the majority having a TSC2 pathogenic variant (n = 39, 38.24%).  A pathogenic 
variant in TSC1 was identified in 26 participants (25.49%).  Sixteen individuals (15.69%) 
reported that they had No Mutation Identified (NMI) by genetic testing while another 
four individuals (3.92%) had a Variant of Uncertain Significance (VUS).   
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Knowledge of TSC 
 When asked about the recurrence risk of TSC, most individuals (n = 147, 85.96%) 
knew that there was a 50% chance of passing on TSC to a child.  Of the individuals who 
did not correctly answer this question, three (1.75%) believed it was a 0% chance, twelve 
(7.02%) believed it was a 25% chance, seven (4.09%) believed it was a 75% chance, and 
two (1.17%) believed it was a 100% chance.  A total of 174 participants answered “yes” 
or “no” to at least one of the symptoms associated with TSC.  The average knowledge 
score was 20.27 out of 24 possible points (86.64%).  Scores ranged between 3 (12.50%) 
and 24 (100.00%) with a median of 22 (91.67%).  Figure 2.3 shows the percent of 
participants who correctly identified each symptom of TSC.  The three most highly 
recognized symptoms of TSC were cortical tubers (98.85%), AMLs (98.28%), and seizures 
(97.70%).  The three least recognized symptoms were forehead plaques (77.01%), 
shagreen patches (77.01%), and LAM (75.29%).   
 Since LAM disproportionately affects one sex, we compared the responses of 
females to males for this symptom.  A chi-square test for association was conducted 
between sex and correctly identifying LAM as a symptom of TSC. All expected cell 
frequencies were greater than five. There was a statistically significant association 
between sex and correctly identifying LAM as a symptom, χ2(1) = 7.49, p = .006. There 
was a negative association between sex and correctly identifying LAM as a symptom, φ = 
-.21, p = .006, with females answering this question correctly more often than males. 
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Reported Symptoms 
 Symptoms experienced by participants are summarized in Table 2.3.  The three 
most commonly reported symptoms included angiofibromas (n = 142, 81.14%), ash-leaf 
spots (n = 132, 67.31%), and AMLs (n = 123, 70.29%).  Cortical tubers were reported by 
102 participants (58.29%).  Seizures, which are often associated with cortical tubers, were 
reported with similar frequency (n = 89, 50.86%).  LAM was reported by 40 individuals 
(22.86%).  Of those 40 individuals, two (5.0%) were male.  Thirty-one participants 
(17.71%) reported other symptoms not included on the provided symptom list.  
Symptoms reported in the “other” category included dental pits, subependymal giant cell 
astrocytomas (SEGA), polycystic kidney disease, and mental health issues.  Since not all 
participants were asked if they experience these symptoms of TSC, we did not calculate 
frequencies of these symptoms. 
 A total of 52 individuals provided symptoms experienced by family members with 
TSC (Table 2.3).  The three most common symptoms reported in family members included 
seizures (n = 36, 69.23%), ash-leaf spots (n = 35, 67.31%), and cortical tubers (n = 31, 
59.62%).  Intellectual disability and autism were reported more frequently in family 
members than participants (44.23% vs. 16.57%, and 30.77% vs. 10.86% respectively).  Skin 
findings (i.e., angiofibromas, forehead plaques, and shagreen patches) were reported 
more frequently in participants than family members. 
Perceived Disease Burden 
 Over half of participants (58.58%) perceived their symptom severity as mild or 
very mild (Figure 2.4).  A minority of participants (10.06%) perceived their symptoms as 
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strong or severe.  In addition to the participant’s perceived disease burden, we employed 
a purpose-designed instrument to measure disease burden/quality of life in individuals 
diagnosed with TSC.  This instrument consisted of 14 questions.  The scale had a high level 
of internal consistency, as determined by a Cronbach’s alpha of .873.  A Pearson’s 
product-moment correlation was run to assess the relationship between symptom 
severity and disease burden/quality of life as measured by the instrument.  Preliminary 
analyses showed the relationship to be linear with both variables normally distributed, as 
assessed by Shapiro-Wilk’s test (p > .05), and there were no outliers.  There was a 
statistically significant, small positive correlation between symptom severity and disease 
burden/quality of life, r(168) = .256, p = .001, with symptoms severity explaining 6.55% of 
the variation in disease burden/quality of life.   
 The highest possible score on the disease burden/quality of life instrument was 
70 and the lowest possible score was 14.  Scores ranged between 16 and 66.  Participants 
had an average score of 39.83 (SD = 11.33) and a median score of 40.  Results of the 
disease burden/quality of life instrument are summarized in Figure 2.5 and Table 2.4. 
Reproductive Decisions 
 Desired number of children. 
 When asked whether they would like to have a child or more children in the future, 
78 (45.09%) responded yes, 70 (40.46%) responded no, and 25 (14.45%) were undecided.  
The 96 participants who answered “yes” or “undecided” were then asked how many total 
children they were considering having. Nineteen (19.79%) responded one, 51 (53.13%) 
responded two, 16 (16.67%) responded three, 8 (8.33%) responded four, and 2 (2.08%) 
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responded five or more.  The average number of desired children was 2.25 and the 
median number was two.  When asked if their desired number of children would be 
different if they did not have TSC, 71 (40.57%) responded yes, 65 (37.14%) responded no, 
and 39 (22.29%) were uncertain.  When asked how many total children they would have 
if they did not have TSC, 6 (5.94%) responded one, 35 (34.65%) responded two, 33 
(32.67%) responded three, 13 (12.87%) responded four, and 14 (13.86%) responded five 
or more.  The average number of desired children if the participant did not have TSC was 
3.12 and the median number was three.   
To assess what factors might be contributing to the participants’ current desired 
number of children, we performed several regression models (Table 2.5).  None of the 
factors investigated had a statistically significant effect on the desired number of children.  
We also wanted to assess whether the participants’ disease burden/quality of life score 
had an effect on how many children they desired if they did not have TSC.  A linear 
regression established that disease burden/quality of life score did not statistically 
significantly predict total number of children desired if the participant did not have TSC, 
F(1, 97) = .362, p = .549.  Disease burden/quality of life score accounted for 4.0% of the 
explained variability in total number of children desired if the participant did not have 
TSC. 
 Reproductive methods being considered. 
 Participants who stated that they were undecided or planned to have future 
children were asked to select which reproductive methods they were considering out of 
traditional conception, adoption, using donor gametes or embryos, and preimplantation 
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genetic diagnosis (PGD).  Participants were able to select more than one option.  A total 
of 102 participants provided a response (Figure 2.6).  Traditional conception was selected 
by 54 (52.94%), adoption was selected by 46 (45.10%), using donor gametes or embryos 
was selected by 18 (17.65%), and PGD was selected by 51 (50.00%).  Two individuals 
(1.96%) selected all four options.  Of the participants who selected only one option, 19 
(18.63%) were only considering traditional conception, 11 (10.78%) were only considering 
adoption, 6 (5.88%) were only considering using donor gametes or embryos, and 17 
(16.67%) were only considering PGD.  To assess what factors might be contributing to the 
participants’ choice of reproductive method, we performed several regression models 
(Table 2.6).  None of the factors investigated had a statistically significant effect on the 
choice of reproductive method.   
 Participants’ stated factors deciding reproductive method. 
 Eighty-nine individuals provided an open-ended response for what factors 
influenced which reproductive method they were considering.  Thematic analysis 
revealed eight themes (Table 2.7).  The most common theme was a desire to not pass on 
TSC to a child which was expressed by 37.08% of respondents.  Personal health or medical 
advice was another major factor expressed by 25.84% of individuals.  Participants who 
were classified into this theme mentioned concerns about kidney health (i.e., increased 
strain on diseased kidney), lung health (i.e., increasing the chance of developing LAM), or 
controlling seizures during pregnancy.  Fertility issues, which affect 10.11% of the 
respondents, were categorized into a separate theme from personal health due to the 
fact these individuals have fewer reproductive options.  Fertility issues included advanced 
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maternal age and personal history of hysterectomy due to complications of TSC.  For 
individuals who received a NMI result, PGD is not technologically possible.  Six individuals 
recognized this limitation.  Other themes included desire for biological children, financial 
concerns, thoughts or desires of partner, and ethical concerns.   Responses which could 
not be categorized into one of the eight themes were classified as “other.”  
 Interest in prenatal testing. 
Participants showed a high level of interest in prenatal testing of a hypothetical 
future pregnancy (Figure 2.7).  A one-way ANOVA was conducted to determine if those 
who would choose to have, would not choose to have, and who were uncertain about 
having prenatal testing had different symptom severity scores. Participants were 
classified into three groups: those who would choose to have prenatal testing (n = 115), 
those who were uncertain about having prenatal testing (n = 26), and those who would 
not choose to have prenatal testing (n = 29). Symptom severity score increased from 
those who would not have prenatal testing (M = 5.59, SD = 3.19), to those who would 
have prenatal testing (M = 6.60, SD = 2.97), to those who were uncertain about having 
prenatal testing (M = 6.85, SD = 2.96), in that order, but the differences between these 
groups were not statistically significant, F(2, 167) = 1.565, p = .212. 
 Participants’ stated factors for prenatal testing decision. 
A total of 142 individuals provided an open-ended response for what factors 
influenced their decision.  Thematic analysis revealed eight themes (Table 2.8).  The most 
common theme was a desire to be informed or prepared which was expressed by 47.18% 
of respondents.  Respondents who were classified into this theme frequently mentioned 
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their own difficult diagnostic odyssey and the benefit of their child growing up with a 
known diagnosis.  Another major theme identified in 21.13% of responses was to possibly 
consider termination.  While only three individuals directly stated that they would 
terminate the pregnancy, others stated that they would not want to be responsible for 
passing on TSC to a child or that they would not want a future child to have to face the 
same decision as themselves.  Other individuals stated that they were accepting of 
whatever happens (8.45% of responses).  Other themes included ethical concerns, the 
risk of invasive testing, financial concerns, testing not being technologically possible in 
their case, and previous experience with prenatal testing. 
 
Discussion 
In this study we set out to assess study participants’: 1) familiarity with the 
symptoms of TSC, 2) understanding of the risk of passing on TSC to a child, 3) perceived 
disease burden/quality of life, and 4) family planning considerations.  To our knowledge, 
this is the only study to assess the familiarity of individuals diagnosed with TSC with the 
broad spectrum of symptoms associated with the condition.  A majority of our study 
population was able to recognize all of the symptoms we assessed.  Unsurprisingly, 
98.85% of participants were familiar with cortical tubers, the hallmark symptom from 
which the condition derives its name.  Interestingly, the second most recognized 
symptom was AMLs, which was identified by more participants (98.28%) than seizures 
(97.70%), ash-leaf spots (95.40%), and angiofibromas (94.25%).  This result is somewhat 
surprising since AMLs are estimated to affect fewer individuals with TSC (52%), than 
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seizures (85%), ash-leaf spots (>90%), or angiofibromas (75%) (Kingswood et al., 2019; 
Wataya-Kaneda et al., 2017).   This disconnect between the prevalence of AMLs in the 
population and the familiarity with the condition is possibly due to the high morbidity and 
mortality associated with the condition.   
A recent study investigating TSC patients’ and parents’ knowledge about AMLs 
had similar results to our study with 93% of individuals reporting that they were aware of 
AML as a symptom of TSC (Cockerell et al., 2018).  However, Cockerell et al. (2018) also 
found that while a majority of patients recognized AML as a symptom of TSC, 42% did not 
know about the associated hemorrhage risk, and 30% were not receiving the appropriate 
renal imaging.  Therefore, it is possible that healthcare providers are diligently informing 
individuals with TSC about the risk of developing an AML due to the high morbidity and 
mortality, but patients may not be fully appreciating the potentially life-threatening 
nature of the condition.  While it has long been known that the risk of hemorrhage 
increases with larger lesion size (typically lesions over 4 cm), the increased risk associated 
with pregnancy has recently been gaining more attention (Ahn, Roberts, Navaratnam, 
Chung, & Wood, 2019; Wang, Li, Peng, Gou, & Fan, 2018).  This risk should be emphasized 
to women with TSC so they can receive appropriate care and monitoring during 
pregnancy.   Our study did not directly assess whether participants were aware of the 
possible severe complications associated with AMLs; however, in our open-ended 
responses to the factors that influenced choice of reproductive method, several 
individuals mentioned concerns about AMLs (see Table 2.7, Personal Health or Medical 
Advice example response).  Our study design does not allow us to assess whether these 
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individuals represent the understanding of the whole study population, or a smaller 
subset like what was found in Cockerell et al.   
Another notable finding from our knowledge assessment was the relatively low 
level of familiarity of study participants with LAM.  Only 75.29% of the participants 
correctly identified LAM as a symptom of TSC.  LAM affects around one third of women 
with TSC, with symptom onset during the reproductive years when women are making 
family planning decisions (Gupta & Henske, 2018; Moir, 2016).  Since LAM 
disproportionately affects women, we compared the responses of males and females to 
this question.  We found a statistically significant difference with women being more likely 
than men to recognize LAM as a symptom of TSC.  This result suggests that medical 
professionals including genetic counselors need to emphasize the risk of developing LAM, 
especially to men with TSC.  While women are far more likely to develop LAM, in rare 
cases men may also develop the condition (Adriaensen, Schaefer-Prokop, Duyndam, 
Zonnenberg, & Prokop, 2011).  In our study, two of our male participants reported having 
LAM.  Even if men are unlikely to develop LAM, there is still risk to future daughters that 
should be understood before reproductive decisions are made. 
The 50% recurrence risk of TSC was understood by a majority of our study 
participants (85.96%).  Three individuals (1.75%) believed that there was no chance of 
having a child with TSC.  While it is possible that an individual can have TSC due to a 
somatic mutation and therefore not necessarily be at risk of passing TSC on, this was not 
the case for these individuals.  One individual had a TSC1 mutation, one did not know his 
or her genetic testing result, and the last individual had not had genetic testing.  These 
33 
individuals’ belief that they could not have a child with TSC suggests they either do not 
understand the genetic nature of their condition, or they are unrealistically optimistic 
about their personal chance of having an affected child.  Twelve individuals (7.02%) 
believed that the recurrence risk was 25%.  It is not clear if these individuals mistakenly 
believed the condition to be recessive, or if they were answering based on a perceived 
personal risk.  Finally, seven individuals (4.09%) believed the recurrence risk was 75%, and 
two individuals (1.17%) believed the recurrence risk to be 100%.  These individuals’ 
responses were likely based on the perception that their personal chance of having a child 
with TSC was high.  Our study did not directly ask participants for their reasoning for the 
recurrence risk.  Therefore, future studies should directly ask participants about why they 
believed the recurrence risk was the number they selected to assess whether individuals 
have a clear understanding of the genetics of TSC, or are answering from a more 
emotional standpoint. 
Over half of our study participants perceived their symptom severity as mild or 
very mild.  This result was consistent with the frequencies of symptoms reported.  While 
literature on TSC suggests over 90% of individuals have cortical tubers and 85% of 
individuals have seizures (Wataya-Kaneda et al., 2017), in our study population only 
58.29% reported cortical tubers and 50.86% reported seizures.  Likewise, the more severe 
neurological complications of intellectual disability and autism were uncommon in our 
study population (16.57% and 10.86% respectively), but closer to the published frequency 
of around 50% in affected family members (44.23% and 30.77% respectively).  The most 
common symptoms in study participants were angiofibromas (81.14%), ash-leaf spots 
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(75.43%), and angiomyolipomas (70.29%).  Unlike seizures or intellectual disability, mild 
skin lesions or AMLs may go unnoticed by both the individual and their health provider 
unless a complication occurs.  While we did not directly ask study participants how they 
came to their diagnosis of TSC, in open-ended responses several individuals mentioned a 
long diagnostic odyssey or discovering their condition after having a child with TSC.  Such 
statements are consistent with having a milder phenotype.  These results are unsurprising 
given the methods and format of our study.  It is unlikely that individuals with severe 
intellectual disability would be actively participating in the online support groups from 
which we recruited study participants.   
Our purpose-designed disease burden/quality of life instrument provided valuable 
insights into the experience of adults with TSC.  A majority of participants reported that 
they felt different from those around them, that they were frustrated by their symptoms, 
that their symptoms made them anxious, and that they thought about their TSC at least 
some of the time.  In addition to the psychological impact on quality of life, TSC also 
impacted the physical quality of life for many participants.  Sleep disturbance was 
common with nearly 40% reporting that they often or very often have difficulty sleeping.  
Around half of participants reported experiencing pain because of their TSC at least some 
of the time.  However, while participants were clearly impacted by their diagnosis, they 
also had a mostly positive outlook.  A majority of participants felt like they were in control 
of their lives, felt good about their social life, and felt comfortable meeting new people.  
The majority of participants also felt like they had the support they needed, which is 
unsurprising given the fact we recruited our participants from support groups. 
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Around 60% of our study population was considering having future children with 
the average desired number of children equaling 2.25.  When asked if this number would 
be different if the individual did not have TSC, around 60% said yes or that they were 
uncertain.  If hypothetically the individual did not have TSC, the average number of 
desired children was 3.12.  To assess what factors may be influencing these differences in 
desired number of children, we performed several regression models looking at the effect 
of symptom knowledge score, symptom severity in the participant and family members, 
and disease burden/quality of life scores.  None of the factors we analyzed had a 
statistically significant effect on the desired number of children.  This suggests that, at 
least for our study population, the desire for children was independent from the 
participant’s experiences with TSC that we measured. 
When asked what reproductive methods they were considering, most participants 
stated they were considering more than one reproductive option, suggesting a strong 
desire to have children in general.  Seventeen individuals (16.67%) were only interested 
in having a child through PGD.  This relatively high level of interest in PGD suggests a 
strong desire to have a biological child who is not affected by TSC.  Our survey did not 
assess whether participants were familiar with PGD before participating in the survey and 
therefore would be aware of the logistics, limitations, and cost associated with the 
procedure.   The desire for a biological child was also clearly evident from the number of 
participants who stated they were only considering traditional conception (19/102, 
18.63%).  It is not clear whether individuals who stated they were only considering 
traditional conception are 1) not concerned about having a child with TSC, 2) are 
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concerned, but are willing to risk the odds, or 3) are concerned, but considering having 
prenatal testing and terminating an affected pregnancy.  Adoption was the only method 
considered for 10.78% of the population.  Individuals considering adoption likely have a 
strong desire for a child, but may not be able to carry a pregnancy, or may have less of a 
psychological need to have a biological relationship to the child either through inheritance 
or through carrying the pregnancy.  Finally, six participants (5.88%) were only considering 
using donor gametes or embryos.  In one open-ended response, the participant 
mentioned that they were in a same-sex relationship.  When designing our questionnaire, 
we failed to account for same-sex couples.  We therefore cannot determine if the 
individuals who stated that they were only considering using donor gametes or embryos 
are same-sex couples or are heterosexual couples interested in having the experience of 
a pregnancy without the risk of passing on TSC to a child.    
In order to assess what factors may be influencing these choices of reproductive 
methods, we performed several regression models.  There was no significant effect of 
symptom severity in the participant, symptom severity in family members, or disease 
burden/quality of life scores on the choice of reproductive method (Table 2.6).  Thematic 
analysis of participants’ responses to what factors influenced their choice of reproductive 
method revealed eight themes (Table 2.7).  The most common theme mentioned by 
37.08% of participants was a “desire to not pass on TSC to a child.”  While these individuals 
could be considering adoption or use of donor gametes or embryos, PGD was often 
specifically mentioned in their open-ended responses.   
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A recent review of patient decision-making factors regarding PGD found that 
patients were highly motivated by the prospect of a healthy child free from the genetic 
condition; however, patients recognized the decision to use PGD was complex (Genoff 
Garzon, Rubin, Lobel, Stelling, & Pastore, 2017).  PGD requires commitment of time, 
money, and emotional resources which may or may not result in a baby.  Ethical concerns 
were also a complicating factor.  Some people expressed ethical concerns about 
discarding affected embryos.  Others stated they felt ethically obligated to use available 
technology to ensure their child would not be affected by a genetic condition.  Our study 
participants provided similar themes to those identified by Genoff Garzon et al. including 
financial and ethical concerns about PGD.  Technology was also a concern, however in our 
study population the concern was that PGD was unavailable for them personally.  PGD 
cannot be used unless the individual has an identified pathogenic mutation.  Therefore, 
our participants who had NMI or a VUS would be unable to utilize this technology.   
The second major theme for their choice of reproductive method mentioned by a 
25.84% of participants was “personal health or medical advice”.  Most responses in this 
category mentioned that pregnancy would be dangerous for them due to AMLs or LAM, 
or that medical professionals recommended they should not have children.  As mentioned 
previously, our study population seemed highly informed about symptoms of TSC and the 
associated risks.  As demonstrated in the example response for this theme, several 
women recognized that the risk of AML rupture increased with pregnancy.  The chance of 
exacerbating LAM also increases with pregnancy.  Therefore, these individuals were often 
considering adopting children. 
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The third major theme was the “desire for biological children” (19.10% of 
responses).  The majority of participants (around 85%) wanted to have a biological child.  
Around a third of participants were only interested in having a biological child, either 
through traditional conception or through PGD.  As mentioned in the example response 
for this theme, individuals who desired biological children often stated that they always 
wanted to be a parent.  Since around 30% of our participants were diagnosed during their 
reproductive years, the desire for biological children likely predates their diagnosis of TSC.  
In our study we did not directly ask whether individuals have changed their mind about 
family plans over the course of their life as they learned more about TSC. 
One theme that was revealed through thematic analysis that we had not 
previously considered was the impact TSC may have on fertility.  As described in the 
example response for the theme of “fertility issues,” some individuals had complications 
of TSC which limited the reproductive options available.  Rare uterine tumors such as 
perivascular epithelioid cell tumors (PEComas) or uterine LAM can occur in women with 
TSC (DeLair & Soslow, 2016).  While the incidence of these tumors is not clearly defined 
in the literature, recent studies suggest they are not uncommon, especially in women 
with LAM.  A study comparing 20 LAM patients found that 90% of the women who had 
been diagnosed with pulmonary LAM have uterine LAM as well (Hayashi et al., 2011).  
Another study found that 18.1% of women under the age of 40 with TSC-associated LAM 
had uterine tumors (Taveira-DaSilva, Rabel, Gochuico, Avila, & Moss, 2011).  In an 
epidemiological study of Japanese patients with TSC, examination of the uterus of 51 
women over the age of 20 by CT and MRI found that 57% had uterine tumors; three 
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women had already undergone radical hysterectomies because of multiple leiomyomas, 
PEComas, and carcinomas (Wataya-Kaneda, Tanaka, Hamasaki, & Katayama, 2013).  
While there are no consensus guidelines on how to treat uterine PEComas or LAM, 
hysterectomy is often performed (Kudela, Biringer, Kasajova, Nachajova, & Adamkov, 
2016; Shan et al., 2019; Taveira-DaSilva et al., 2011).  Therefore, for women with TSC the 
ability to carry a pregnancy may be at risk due to complications of the condition.  
Additionally, several women mentioned delaying starting a family due to health concerns 
(i.e., seizure control) and therefore having limited fertility due to age.  These results 
suggest fertility concerns and gynecological health should be addressed when counseling 
women with TSC, especially during their reproductive years. 
Our study population showed a high level of interest in prenatal testing with 
67.44% stating they would have prenatal testing in a hypothetical future pregnancy and 
15.12% stating they were uncertain.  When we compared symptom severity scores to 
interest in prenatal testing, we found a positive trend with severity scores increasing from 
those who are not interested in testing to those who are interested in testing.  However, 
the differences in severity scores were not statistically significant.  Thematic analysis of 
factors that participants stated influenced their decisions about prenatal testing revealed 
eight themes.   
The most common theme which was expressed in 47.18% of responses was “being 
informed or prepared.”  Many of the responses which were classified into this theme 
mentioned the long diagnostic odyssey that the participant experienced to reach their 
TSC diagnosis.   These participants stated that they did not want their child to go through 
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the same experience.  Like the example response for this category, many participants 
stated that they wanted to know before the baby was born to obtain the appropriate 
medical care for their child from birth and to prepare their lives for the possibility of a 
more severely affected child. 
The second most common theme which was expressed by 21.13% of participants 
was considering termination if the pregnancy was affected.  Only three participants 
directly stated that they would terminate an affected pregnancy.  Other participants who 
were placed into this theme stated that they did not want to be responsible for passing 
on TSC to a child.  Due to the context of the question, these responses were assumed to 
mean that the participant would terminate the pregnancy to prevent their child from 
being born with TSC.  One participant stated that they would not want their child to have 
to face the same decision.  This participant was therefore preventing their child from 
having the possible psychological burden of deciding whether or not to risk having a more 
severely affected child by ensuring that their child was born without TSC. 
The third most common theme was being accepting of whatever happens which 
was expressed by 8.45% of the participants.  This theme was the most common response 
of individuals who would not consider prenatal testing.  Many individuals stated that they 
would be happy to be a parent no matter what the outcome.  Others stated that the 
outcome was in God’s hands.   
In addition to the three major themes, we identified five minor themes.  Four of 
the themes were reasons why individuals were not interested in prenatal testing.  These 
themes included ethical concerns about testing, concerns about the risk of invasive 
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testing, financial concerns, and testing not being technologically possible in their case.  
The final theme identified was previous experience with prenatal testing which was 
expressed by individuals who were interested in prenatal testing.  All four of these 
individuals had previously used prenatal testing for TSC in a pregnancy.  At least one of 
these participants decided to terminate the affected pregnancy (see example response, 
Table 2.8). 
Practice Implications 
 The results of this study suggest there are several areas where genetic counselors 
and other healthcare providers can help fill in knowledge gaps for adults with TSC.  In 
particular, our study showed that men with TSC are less familiar with 
lymphangioleiomyomatosis.  While men are much less likely to develop LAM, it is still a 
potential health risk.  LAM would also pose a risk to future daughters, and therefore men 
should be aware of this risk before making family planning decisions.  It is also important 
to emphasize the 50% recurrance risk to individuals with TSC so they can make informed 
reproductive decisions.  While most of our study participants were aware of this risk, 
around 15% believed the risk to be higher or lower than 50%.  These individuals might be 
making reproductive decisions that they otherwise would not make if they knew the 
actual recurrence risk.   Finally, our thematic analysis revealed that fertility issues for 
individuals with TSC should be addressed more often by healthcare providers.  In 
particular, women of reproductive age should be informed about the chance of 
developing uterine tumors which may require surgical excision or hysterectomy.  If 
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women are made aware of this potential complication of TSC, they might decide to start 
their family at a younger age. 
 Our study showed that individuals with TSC are highly motivated to have biological 
children.  Many of our study participants were interested in using available reproductive 
technologies such as PGD or prenatal diagnosis.  While many people view these 
technologies in a very positive light, they still have limitations and barriers to their use.  
One major barrier is cost, particularly for the IVF which is required to perform PGD.  
Another important barrier is the fact that individuals must know their pathogenic variant 
to utilize these technologies.  In our study, over half of the participants (58.29%) had 
genetic testing.  However, this number is less than the number of individuals who stated 
that they wanted prenatal testing in a future pregnancy (67.44%).  It is important to 
emphasize to individuals with TSC that a pathogenic mutation must first be identified in 
the affected parent before PGD or prenatal testing can be performed.  While the parent 
could decide to have genetic testing at the time of pregnancy, this could add delay to the 
prenatal testing process which could potentially eliminate the possibility of terminating a 
pregnancy if the family wished.   
Genetic counselors also need to emphasize that genetic testing may not find a 
pathogenic variant.  In our study population, a pathogenic variant was identified in only 
63.73% of individuals tested.  This number is also below the number of individuals who 
were interested in prenatal diagnosis, indicating that some of the individuals who would 
want prenatal testing would not be able to utilize this technology.  While it is possible to 
identify affected pregnancies by ultrasound or fetal MRI (Dragoumi, O'Callaghan, & 
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Zafeiriou, 2018), it is important to emphasize to parents that there are limitations to all 
technologies and prenatal diagnosis may not be possible in all cases.  It is possible that 
some individuals do not realize this limitation and are making reproductive decisions 
based on the assumption that these technologies would be available. 
Study Limitations 
 Our study had several limitations.  One limitation is the fact that participants were 
recruited through the World TSC Conference and support groups and therefore are more 
likely to be highly engaged in their diagnosis.  This high level of engagement likely lead to 
participants being more aware of the range of clinical symptoms that can occur in TSC and 
more likely to know other individuals with TSC symptoms different from their own.  This 
high level of awareness is likely not the case in the general population of individuals with 
TSC.  Therefore, our results may not be representative of the adult TSC population as a 
whole.  The high level of awareness of symptoms of TSC might also be inaccurate due to 
the fact this survey was conducted online.  It is possible that participants researched 
symptoms of TSC as they were taking the survey, thereby skewing the results of the TSC 
symptoms knowledge score. 
 Participant demographics were also somewhat skewed.  A large majority (78.29%) 
of study participants were female.  This result is unsurprising given the fact that women 
tend to be more active in support groups than men.  However, since men and women are 
equally affected by TSC, our results may not be reflective of the adult TSC population as 
a whole.  Our participants were also highly educated with 42.44% having a bachelor’s 
degree or higher.  This is significantly higher than the 34% of Americans who have a 
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bachelor’s degree or higher according to the US Census Bureau (Schmidt, 2018).  This 
education bias is likely also due to the fact we recruited from support groups and the 
World TSC Conference which are more likely to attract highly engaged and educated 
individuals.  Due to the high level of education in our study group, it is possible that the 
results of this study are not representative of the general population of adults with TSC. 
 Another major limitation is the potential for misinterpreting open-ended 
responses to the questionnaire.  For example, when asked about prenatal testing for a 
hypothetical future pregnancy, many individuals stated that they did not want to have a 
child with TSC.  Due to the context of the question, this was interpreted as considering 
termination of the pregnancy if affected.  However, the participants may have 
misinterpreted the question as asking if they would actively choose to have a future 
pregnancy, not that in this scenario the pregnancy had already happened.  Since we were 
unable to ask follow-up questions for answers that were unclear, it is possible that our 
interpretation of the response was inaccurate. 
 Finally, since this was an anonymous online survey, it is possible that responses 
provided were not those of the individual diagnosed with TSC.  In our survey, 29 
individuals (16.57%) reported that they have intellectual disability.  This result is 
somewhat surprising given that the questionnaire’s language level and format would 
likely prove difficult for individuals with special needs.  While it is possible that these 
individuals have a  borderline diagnosis and were able to respond on their own or with 
some assistance, most likely these responses were provided by family members on the 
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individual’s behalf.  Therefore, the responses to this questionnaire may not reflect these 
individual’s actual opinions and feelings. 
Research Recommendations 
 This study was the first of its kind to investigate knowledge, disease burden, and 
reproductive decisions in adults with TSC.  More research is needed to better understand 
the adult population.  Most published studies focus on children diagnosed with TSC.  
Individuals who are diagnosed as children typically have more severe symptoms such as 
infantile spasms or intellectual disability which brings them to medical attention sooner.   
In order to better address concerns of mildly affected adults with TSC, we need more data 
on which symptoms these individuals experience and how these symptoms affect their 
daily lives.  As demonstrated by our disease burden/quality of life instrument, TSC can 
have both physical and psychological impacts on even mildly affected adults.  In order to 
better counsel adults with TSC, we need to know how TSC is impacting their lives.  In 
particular, we need more studies investigating the impact of uterine tumors on the 
reproductive health of women with TSC. 
Future studies should also investigate uptake of genetic testing in adults with TSC, 
and genetic testing results.  In our study TSC2 pathogenic mutations were only found in 
38.24% of individuals who had genetic testing.  This is significantly lower than the 
estimated 51-82% of individuals with TSC2 pathogenic variants which is currently cited in 
the literature (Caban et al., 2017).  While there is overlap in symptoms for TSC1 and TSC2 
pathogenic variants, generally speaking, individuals with TSC2 pathogenic variants have 
an earlier onset of seizures, lower cognitive scores, more skin lesions, and greater tumor 
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burden in the brain, kidneys, and liver (Caban et al., 2017).  Therefore, it is possible that 
mildly affected adults with TSC are less likely to have a TSC2 pathogenic variant than the 
general TSC population. 
When it comes to reproductive decisions in adults with TSC, there were a few gaps 
in our study which should be addressed by future research.  Future research should 
consider recruiting participants from a wider population such as at a TSC clinic or specialty 
care center where individuals are being treated for their symptoms of TSC.  By recruiting 
from both support groups and clinic settings, study participants may be more 
representative of the general population of adults with TSC.  Future studies should also 
consider using either more open-ended responses or an interview format to better 
understand the thought processes of participants.  Finally, future studies should ask 
participants who were diagnosed with TSC in adulthood whether their reproductive 
decisions have changed over the course of their life. 
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Tables 
 
Table 2.1 Summary of Participant Demographics 
 
 
Category Response 
Participants  
(N) 
Percentage 
(%) 
Age 
20 and Under 15 8.57 
21-25 29 16.57 
26-30 36 20.57 
31-35 31 17.71 
36-40 35 20.00 
41 and Over 29 16.57 
Total 175 100 
Sex 
Female 137 78.29 
Male 35 20.00 
Prefer Not to Answer 3 1.71 
Total 175 100 
Relationship Status 
Single, never married 57 33.14 
In a Serious Relationship or Engaged 38 22.09 
Married or in a Domestic Partnership 70 40.70 
Separated or Divorced 7 4.07 
Total 172 100 
Highest Education 
Level Attained 
Some High School 8 4.65 
High School Diploma or GED 30 17.44 
Some College 34 19.77 
Vocational, Technical, or Trade School 10 5.81 
Associate’s Degree 17 9.88 
Bachelor’s Degree 46 26.74 
Graduate or Professional Degree 27 15.70 
Total 172 100 
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Table 2.2 Participants’ Current Family Structure 
Fifty-three participants (30.29%) currently have children.  Fifty-eight participants (33.14%) 
reported at least one affected family member.  Percentages represent the number of participants 
who gave the specified response out of the total survey population (n = 175). 
 
 
 
Category Response 
Participants  
(N) 
Percentage  
(%)  
Current Number of Children 
None 122 69.71 
One 21 12.00 
Two 23 13.14 
Three 8 4.57 
Four 1 0.57 
 
   
Family Members Diagnosed 
with TSC 
Parent 34 19.43 
Sibling 15 8.57 
Child 30 17.14 
Other Family 23 13.14 
Any Family Member Affected 58 33.14 
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Table 2.3 Summary of Participant’s and Family Member’s Symptoms   
Percentages represent the number of participants who reported the specified symptom for 
themselves out of the total who reported symptoms (n = 175) or the specified symptom for 
affected family member(s) out of the total who reported symptoms for family members (n = 52). 
 
Symptom Affected Individual Individuals (N) Percentage (%)  
Angiofibromas 
Self 142 81.14 
Family Member 22 42.31 
Angiomyolipomas 
Self 123 70.29 
Family Member 22 42.31 
Ash-Leaf Spots 
Self 132 75.43 
Family Member 35 67.31 
Autism 
Self 19 10.86 
Family Member 16 30.77 
Cardiac Rhabdomyomas 
Self 39 22.29 
Family Member 18 34.62 
Cortical Tubers 
Self 102 58.29 
Family Member 31 59.62 
Developmental Delay 
Self 38 21.71 
Family Member 25 48.08 
Forehead Plaques 
Self 75 42.86 
Family Member 4 7.69 
Intellectual Disability 
Self 29 16.57 
Family Member 23 44.23 
Learning Disability 
Self 71 40.57 
Family Member 28 53.85 
Lymphangioleiomyomatosis 
Self 40 22.86 
Family Member 7 13.46 
Periungual Fibromas 
Self 89 50.86 
Family Member 20 38.46 
Seizures 
Self 89 50.86 
Family Member 36 69.23 
Shagreen Patches 
Self 89 50.86 
Family Member 23 44.23 
Subependymal Nodules 
Self 51 29.14 
Family Member 18 34.62 
Other Symptom(s) 
Self 31 17.71 
Family Member 9 17.31 
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Table 2.4 Disease Burden/Quality of Life Average Score by Question 
Participants were asked how often they agree with the statement listed on a five point scale of 
“never” to “very often.”  Negative statements were scored 1 for “never” to 5 for “very often.”  
Positive statements (*) were scored in reverse. 
 
Statement Average Median 
I feel like I am in control of my life. * 2.44 2 
I think about my TSC. 3.78 4 
I tend to stay home because of my symptoms. 2.35 2 
My symptoms limit the things I can do. 2.61 3 
I worry about my appearance. 2.80 3 
I have trouble sleeping. 3.21 3 
I feel comfortable meeting new people. * 2.77 3 
I feel good about my social life. * 2.84 3 
I feel different from those around me. 3.35 3 
I had trouble in school. 2.98 3 
I feel like I have the support I need. * 2.40 2 
I am frustrated by my symptoms. 3.26 3 
I experience pain because of my TSC. 2.57 3 
My symptoms make me anxious. 3.12 3 
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Table 2.5 Summary Table of Regression Models of the Effect of Various Factors on 
Participants’ Desired Number of Children 
None of the factors investigated had a statistically significant effect on the participants’ desired 
number of children. 
 
 
 
Variable F df p R2 
Knowledge Score 0.421 (1, 93) .518 .005 
Symptom Severity Score 2.566 (1, 97) .112 .026 
Facial Symptom Severity Score 0.872 (1, 101) .353 .009 
Seizures in Participant 0.001 (1, 101) .978 .000 
Disease Burden/Quality of Life Score 0.884 (1, 97) .350 .009 
Symptom Severity in Family 0.442 (1, 101) .507 .004 
Family History of Autism 0.052 (1, 101) .820 .001 
Family History of Intellectual Disability 0.166 (1, 101) .684 .002 
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Table 2.6 Summary Table of Regression Models of the Effect of Various Factors on 
Participants’ Choice of Reproductive Method 
None of the factors investigated had a statistically significant effect on the participants’ choice of 
traditional conception, adoption, use of donor gametes or embryos, or preimplantation genetic 
diagnosis. 
 
Variable 
Reproductive 
Method 
F df p R2 
Symptom Severity Score 
Traditional 0.152 (1, 98) .697 .002 
Adoption 0.005 (1, 98) .946 .000 
Donor 0.161 (1, 98) .689 .002 
PGD 0.365 (1, 98) .547 .004 
      
Disease Burden/Quality of Life Score 
Traditional 0.232 (1, 96) .631 .002 
Adoption 2.384 (1, 96) .126 .024 
Donor 0.054 (1, 96) .816 .001 
PGD 1.460 (1, 96) .230 .015 
      
Symptom Severity in Family 
Traditional 0.034 (1, 98) .855 .000 
Adoption 0.827 (1, 98) .365 .008 
Donor 0.003 (1, 98) .956 .000 
PGD 0.635 (1, 98) .427 .006 
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Table 2.7 Themes Identified as Factors for Choice of Reproductive Method 
Eighty-nine individuals provided an open-ended response for what factors influenced which 
reproductive method they were considering.  Thematic analysis revealed eight major themes.  
Some statements could be coded into multiple themes.  Statements which did not fit into a theme 
were classified as “other.” 
 
Theme Example Response 
Participants  
(N) 
Percentage 
(%) 
Personal Health or 
Medical Advice 
“Pregnancy would be dangerous for 
me with my renal AMLs, and wouldn't 
help my odds of developing LAM 
(which I do not have yet, but some 
research links it and estrogen levels).“ 
23 25.84 
Desire to Not Pass on 
TSC to a Child 
“I don’t want to risk my children 
inheriting TSC. I knew I wanted to do 
PGD at age 21 when I first found out 
that it was possible.” 
33 37.08 
Financial Concerns 
“I would like tradition [sic], because 
money is a huge factor in this. I have 
looked up PGD and it seems 
expensive.” 
9 10.11 
Desire for Biological 
Children 
“I've always wanted to be a mom and 
although I'm not opposed to adoption 
and would love them just as much, I 
would prefer to have my own kids.” 
17 19.10 
Thoughts/Desires of 
Partner 
“My partners will [sic] to take the risk.” 9 10.11 
Ethical Concerns 
“I don't like the idea of discarding 
unhealthy eggs which have be [sic] 
fertilized in the PGD process.” 
2 2.25 
Not Technologically 
Possible 
“PGD not available because I have 
NMI.” 6 6.74 
Fertility Issues 
“I had a hysterectomy almost 2 years 
ago.  I had a Pecoma.” 9 10.11 
Other 
“I have a sister who is adopted and I 
have tremendous anxiety about 
putting my body through pregnancy.” 
23 25.84 
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Table 2.8 Themes Identified as Factors for Decisions About Prenatal Testing 
A total of 142 individuals provided an open-ended response for what factors influenced whether 
they would undergo prenatal testing for TSC in a hypothetical future pregnancy.  Thematic 
analysis revealed eight major themes.  Some statements could be coded into multiple themes.  
Statements which did not fit into a theme were classified as “other.” 
 
Theme Example Response 
Participants  
(N) 
Percentage 
(%) 
Possibly Considering 
Termination 
“TSC is a terrible chronic disease. I do 
not want to be responsible for 
knowingly bringing a child(ren) into 
this world who is affected by this 
condition. Mild case or severe case. 
Does not matter to me.” 
30 21.13 
Ethical Concern/ 
Against Termination 
“I don't believe in abortion and would 
love the child regardless of the TSC.” 4 2.82 
Being Informed/ 
Prepared 
“I would want to be prepared, 
including finding a medical team, if my 
child were to be diagnosed with TSC. I 
would also want to be able to prepare 
my life and home for the possibility of 
a child with severe delays.” 
67 47.18 
Previous Experience 
“I have already done that, and ended a 
pregnancy because the tests showed 
TSC2.” 
4 2.82 
Risk of Test 
“Amnio has risks, and may not yield a 
result anyway since I don't know my 
mutation.” 
4 2.82 
Financial Concern “genetic testing is expensive” 4 2.82 
Not Technologically 
Possible 
“I did not test positive for the gene. I 
was clinically diagnosed based on 
multiple issues.” 
4 2.82 
Accepting of 
Whatever Happens 
“The results wouldn't change my 
happiness.” 12 8.45 
Other 
“I would consider testing after the 
baby were [sic] born.” 
25 17.61 
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Figures 
 
 
 
Figure 2.1 Participants’ Age at Diagnosis of TSC   
Participants (n = 175) were asked if they were diagnosed prenatally, under one year of age, or 
over one year of age.  Those diagnosed over one year were asked to provide age in years.  The 
median age at diagnosis was 7 years.  
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Figure 2.2 Genetic Testing Result of Participants 
A total of 102 participants reported having genetic testing.  Participants reported that their 
genetic test found either a pathogenic mutation in TSC1 (n = 26) or TSC2 (n = 39), a Variant of 
Uncertain Significance (VUS) (n = 4), or No Mutation Identified (NMI) (n = 16).  A total of 17 
participants were unable to remember their testing result. 
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Figure 2.3 Results of the TSC-Associated Symptoms Quiz 
The percent of participants who correctly identified the listed symptom is based on the total number of participants who provided at least one 
answer to this question (n = 174).  Some participants did not provide an answer for each symptom.
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Figure 2.4 Participants’ Perceived Symptom Severity 
Participants were asked to rate their symptom severity on a five point scale of “very mildly” to 
“severely” affected.   A total of 169 participants provided a response: very mildly (n = 45), mildly 
(n = 54), moderately (n = 53), strongly (n =12), and severely (n = 5).
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Figure 2.5 Perceived Impact of TSC on Participants’ Lives 
Participants were asked how often they agreed with the statement on a five point scale ranging from “never” to “very often.” 
The number of participants who agreed with each option is indicated at the end of each bar.
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Figure 2.6 Reproductive Methods Being Considered 
Bars represent the number of participants considering traditional conception, adoption, using 
donor gametes or embryos, and/or preimplantation genetic diagnosis (PGD).  Participants were 
able to select more than one response.  A total of 102 participants provided a response. 
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Figure 2.7 Participants’ Interest in Prenatal Testing for TSC 
Participants were asked whether they would consider prenatal testing of a hypothetical future 
pregnancy.  Out of 172 responses, 116 said yes, 30 said no, and 26 were uncertain. 
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15.12%
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Appendix A 
 
Recruitment Flyer: 
 
Are you an adult aged 18-45 diagnosed 
with tuberous sclerosis complex (TSC)? 
We would like to hear from you! 
 
 While a lot of research has been done on the medical aspects of tuberous sclerosis complex 
(TSC), not much has been done on how TSC affects people’s lives.  I would like to change that.  I am 
a genetic counseling student at the University of South Carolina.  From July-December 2018 I will be 
conducting an anonymous online survey to better understand how TSC affects adults aged 18-45 in 
their daily lives including family planning.  This survey is completely voluntary.  It will include questions 
about the following topics: 
 
• basic demographics (age, sex, education level, etc.) 
• symptoms that occur in TSC 
• symptoms that you and your affected family members experience 
• how TSC affects your daily life 
• how TSC affects your family planning 
 
The survey takes about 8-10 minutes to complete.  Participants have the opportunity to enter 
a drawing for a $25 Amazon e-gift card.  The drawing will be conducted once the survey period has 
ended in December 2018.  To enter the drawing participants will need to provide an email or cellphone 
number, however the survey can be taken without providing contact information.  Your contact 
information will not be shared or used for any other purpose than to notify you if you win the drawing. 
 
To participate in the survey, please go to the following website: 
https://www.surveymonkey.com/r/Adults_with_TSC 
If your smart phone or tablet has a QR Reader you can use this link:  
 
If you have any questions about the survey, please contact Diane Biederman 
 at Diane.Biederman@uscmed.sc.edu 
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Appendix B 
 
SurveyMonkey.com Anonymous Online Survey: 
 
 
Welcome to the Adults with TSC Survey! 
     Thank you for your interest in our survey!  We are conducting this survey in order to better understand how 
adults are affected by tuberous sclerosis complex (TSC) in their daily lives including family planning.  This survey is 
anonymous and completely voluntary.  You may choose to stop at any time or skip any questions that you do not 
wish to answer (except questions 1 and 2 which are required to meet survey participation requirements).  To 
participate, you should be an adult aged 18-45 who has been diagnosed with TSC.  This survey is intended to get 
the opinions of people who have TSC themselves.  While parental or spousal opinions can be important factors, 
we ultimately want your opinion so please answer for yourself. 
  
The survey is divided into 5 sections: 
1) Demographics:  basic questions about you such as age, sex, education level, etc. 
2) Family Planning:  questions about your plans for children 
3) Features of TSC:  includes general questions about TSC and symptoms experienced by you or your family 
members 
4) Your experience with TSC:  questions about how TSC affects your daily life 
5) Closing Statement:  how did you hear of the survey and entry into Amazon e-gift card drawing 
     It will take about 10 minutes to complete the survey.  At the end of the survey, you will have the opportunity 
to enter a drawing for a $25 Amazon e-gift card.  Entry into the drawing will require either an email or mobile 
phone number to be provided for delivery purposes.  Your contact information will not be used for any other 
reason or shared with any other parties.  You do not have to provide your contact information to complete the 
survey, however without contact information, you will not be entered into the drawing. 
  
     This survey is being conducted as part of a research thesis for Diane Biederman, a genetic counseling student at 
the University of South Carolina.  If you have any questions or concerns about the survey before you begin, please 
email Diane at Diane.Biederman@uscmed.sc.edu. 
  
By clicking "next" you are agreeing to participate in this survey. 
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Survey Eligibility 
Please answer the following questions to determine if you meet the survey requirements. 
* 1. Have you been diagnosed with tuberous sclerosis complex (TSC)? 
Yes 
* No 
* 2. Are you between the ages of 18-45? 
    Yes 
No   
Part 1: Demographics 
3. What is your current age? 
 
4. Are you biologically male or female? 
  Male 
  Female 
  Prefer not to answer 
5. Are you in a relationship? 
   Single, never married 
   In a serious relationship or engaged 
   Married or in a domestic partnership 
6. What is your highest level of education? 
          Some high school 
   High school diploma or GED 
   Some college 
 
 
 
 
Separated or Divorced 
Widowed 
Vocational, technical, or trade 
school 
Associate’s degree 
Bachelor’s degree 
Graduate or professional degree 
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7. When were you diagnosed with TSC? 
If you are not sure, please give your best guess. 
 
 
8. Has anyone else in your family been diagnosed with TSC?   
Please enter the number of individuals in each category who have been diagnosed with TSC.  If you do 
not have family members with TSC, please leave blank. 
 
 
9. Have you had genetic testing for your TSC? 
(A DNA test to identify the cause of your TSC) 
 Yes 
 No 
 I don't know
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Part 1: Demographics 
10. What was the result of your genetic test? 
I have a pathogenic (disease-causing) change in TSC1.  
 I have a pathogenic (disease-causing) change in TSC2.  
They found a change, but are not sure if it caused my TSC. (This may have been called a "variant of uncertain 
significance" or "VUS" by your doctor.) 
The test didn't find any changes in myTSC1 orTSC2 genes. 
I don't know/remember my result. 
 
Part 2: Family Planning 
The following questions are about your plans for your current or future family. 
11. How many children do you currently have? 
 
 
12. Would you like to have (or have more) children in the future? 
(may be biological or not biological) 
 Yes 
 No 
 Undecided 
13. When thinking about your future family, how many children would you like to have in total? 
Please enter the number in the space provided.  If "undecided", please enter your "maybe" 
number. 
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14. Which of the following reproductive options are you considering?  
Select all that apply. 
Traditional conception 
Adopted children 
Using donor eggs, sperm, or embryos (having a pregnancy that is not biologically related to you) 
Preimplantation genetic diagnosis (PGD)  
PGD is a procedure that uses IVF to create embryos which are then tested for a genetic condition that runs in the 
family. Typically, the embryos which do not have the condition will be selected for implantation.  This procedure 
lets families have biological children who will not have the genetic condition. 
15. What factors determined your answer to question 14? 
 
The following questions are hypothetical.  What would you do in the following situations? 
16. If you did not have TSC, would the number of children you would like to have be different? 
 Yes 
 No 
 Uncertain/Maybe 
 
17. How many children would you like to have in total if you did not have TSC? 
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18. If you or your partner were to become pregnant, would you consider testing your baby for TSC 
before he or she is born? 
Prenatal testing (testing before birth) would involve collecting a sample of the baby's DNA by 
amniocentesis (collection of amniotic fluid from the womb) or chorionic villus sampling (collecting a 
sample of the placenta), growing the sample in a lab, and then testing the baby's DNA for a known 
change to the TSC1 or TSC2 genes. 
 Yes 
 No 
 Uncertain 
19. What factors determined your answer to question 18? 
 
Part 3: Features of TSC 
The following questions are intended to measure how familiar people diagnosed 
with TSC are with features of the condition.  Please answer based on your current 
understanding of symptoms of TSC.  Please do not look up symptoms.  If you are 
not sure, please give your best guess.  While medical terminology will be used, a 
short description will be provided for each condition. 
Please note: the symptoms listed below may or may not be associated with TSC.  
The list also may not include all symptoms associated with TSC.  If you have any 
questions or concerns about potential symptoms of TSC, please contact your 
healthcare provider, a genetic counselor, or a TSC clinic.  
  
     To find a genetic counselor, click here.    
     To find a TSC clinic, click here. 
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20. Which of these symptoms can be caused by TSC? 
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Forehead plaques or  
cephalic plaques: smooth patches 
of raised skin on the forehead,  
scalp, or face which may be red or  
flesh colored 
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   Learning difficulty:  
   when an individual has problems  
   in school with skills like reading or  
   math, but is still able to live a
 
  Subependymal nodules (SEN): 
  Benign (noncancerous) tumors  
  growing in the walls around the  
  ventricles (fluid-filled spaces) in  
  the brain 
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21. If you were to have a biological child with a partner who does not have TSC, what is the chance 
your child would have TSC? 
 
0% or "I can't have a child with TSC." 
25% or "1 in 4 chance" 
75% or "3 in 4 chance" 
 100% or "I am guaranteed to have a  
 child with TSC." 
   50% or "1 in 2 chance" 
The next questions are about symptoms of TSC you or your family members 
experience. The symptoms listed are the same as in question 20 and may or may 
not be associated with TSC.  The list may not include all symptoms of TSC. 
22. What symptoms of TSC do you and your family members experience?  
Select all that apply. If you are unsure about a symptom, please leave the option blank. 
                                                                I have this symptom.                     One or more family members have this symptom.
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Forehead plaques or  
  cephalic plaques:  
  smooth patches of raised skin  
  on the forehead, scalp, or face  
  which may be red or flesh colored
 
   Learning difficulty: 
   when an individual has problems 
   In school with skills like reading 
   or math, but is still able to live 
   a typical independent life 
 
 
(COPD) 
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  Subependymal Nodules (SEN): 
   Benign (noncancerous) tumors  
   growing in the walls around the  
   ventricles (fluid filled spaces) in  
   the brain 
 
  Other (please note if the symptom is yours, a family member's, or both) 
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Part 4: Your experience with TSC 
The following questions are about how TSC affects your daily life. 
23. How would you characterize your own symptoms of TSC? 
 Very mildly affected 
 Mildly affected 
 Strongly affected 
 Severely affected 
 Moderately affected 
 
24. Thinking about your experience with TSC, how often would you agree with the following 
statements? 
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Part 5: Closing Statement 
Thank you for completing this survey! Your time and responses are greatly appreciated and will 
help us better understand the adult TSC population.  Before you go... 
25. How did you hear about this survey? 
 A flyer at the 2018 World TSC Conference 
 Through an online support group/online newsletter. 
 A flyer at a TSC clinic 
 Through a friend 
26. Would you be open to a possible follow-up interview? 
If yes, please make sure to enter your contact information (mobile phone or email) in the Amazon 
e-gift card drawing.   
If no, still enter the drawing.  We promise not to contact you unless you win. 
 
Yes 
No 
27. If you would like to enter the $25 Amazon e-gift card drawing, please provide an email or 
mobile phone number where we can send your prize.  
Your contact information will not be used for any purpose other than the drawing or to contact you 
if you agreed to a follow-up interview.  Your information will not be shared with any other parties.  
If you are concerned that your email may reveal your identity, please provide a mobile phone 
number instead. 
 
 
